UBS Group
CYT

UBS Group’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

UBS Group’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,267
Closed -$13.7K – 10180
2023
Q2 		$13.7K Buy
5,267
+442
+9% +$925 ﹤0.01% 7034
2023
Q1 		$8.78K Buy
+4,825
New +$7.84K ﹤0.01% 7700
2022
Q4 		– Sell
-34,809
Closed -$67K – 11366
2022
Q3 		$67K Buy
34,809
+5,473
+19% +$14.3K ﹤0.01% 6072
2022
Q2 		$88K Sell
29,336
-2,345
-7% -$5.99K ﹤0.01% 5528
2022
Q1 		$120K Sell
31,681
-2,930
-8% -$16.7K ﹤0.01% 5767
2021
Q4 		$394K Buy
34,611
+34,192
+8,160% +$521K ﹤0.01% 5176
2021
Q3 		$7K Sell
419
-31
-7% -$579 ﹤0.01% 8352
2021
Q2 		$10K Buy
+450
New +$8.43K ﹤0.01% 8071

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

UBS Group's CYT Position: Q3 2023 in Review

UBS Group sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 5,267 shares — an estimated $13.7K sold.

UBS Group first reported a position in CYT in Q2 2021 and held it in 8 quarters. The position peaked at $394K in Q4 2021. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

  • UBS Group reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 5,267 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $13.7K.
  • UBS Group first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
  • UBS Group's Cyteir Therapeutics, Inc. Common Stock position peaked at $394K in Q4 2021.
  • 41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.